retatrutide clinical trials weight loss results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Effects of once-weekly subcutaneous retatrutide

While clinical trials for FDA approval for use of GLP-1/GIP medications in the treatment of T1D are ongoing, the consensus statement emphasizes several key principles for safe use in the meantime: Insulin safety comes first People with type 1 diabetes should never stop taking insulin while using a GLP-1 or GIP medication

pmid:20384817 36

Headache, usually resolving in the first 2 weeks

Food and Drug Administration has recorded 209 incidents of Wegovy patients suffering from gastrointestinal disorders this year, 42 of whom were hospitalized

RPh & Owner, Former CDE & CGP | Minor Ailments | Patient Education | Former OCP Board Member | Faith-Driven Healthcare Advocate Sandoz to Slash Generic Semaglutide Prices What It Means for Community Pharmacies & Patients in Canada Sandozs plan to launch low-cost generic semaglutide (up to 6070% cheaper) could reshape how Canadians access weight-loss and diabetes care

Note: A 4.5 mg weekly dose draws nearly the whole vial in a single injection